Zevra Therapeutics (NASDAQ:ZVRA) Director Sells $138,375.00 in Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Director Corey Michael Watton sold 12,300 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $11.25, for a total value of $138,375.00. Following the sale, the director owned 1,800 shares of the company’s stock, valued at $20,250. This represents a 87.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Zevra Therapeutics Trading Up 0.9%

ZVRA traded up $0.10 on Wednesday, hitting $11.44. 697,529 shares of the company’s stock traded hands, compared to its average volume of 1,355,583. The company’s 50 day simple moving average is $12.33 and its 200-day simple moving average is $10.62. Zevra Therapeutics, Inc. has a one year low of $7.16 and a one year high of $15.03. The firm has a market cap of $679.35 million, a price-to-earnings ratio of 12.43 and a beta of 0.91.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.14. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%.The business had revenue of $39.66 million during the quarter, compared to the consensus estimate of $33.88 million. As a group, equities analysts anticipate that Zevra Therapeutics, Inc. will post 0.6 EPS for the current fiscal year.

Institutional Trading of Zevra Therapeutics

A number of large investors have recently made changes to their positions in the business. Bank of New York Mellon Corp purchased a new stake in shares of Zevra Therapeutics during the 2nd quarter valued at about $2,846,000. Hennion & Walsh Asset Management Inc. grew its position in Zevra Therapeutics by 116.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock worth $5,502,000 after acquiring an additional 206,543 shares in the last quarter. Quantinno Capital Management LP increased its stake in Zevra Therapeutics by 114.1% during the first quarter. Quantinno Capital Management LP now owns 32,022 shares of the company’s stock worth $298,000 after acquiring an additional 17,065 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Zevra Therapeutics by 259.2% during the first quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock worth $5,168,000 after acquiring an additional 400,336 shares during the last quarter. Finally, AIGH Capital Management LLC purchased a new stake in Zevra Therapeutics during the first quarter valued at approximately $11,184,000. 35.03% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently weighed in on ZVRA shares. Canaccord Genuity Group cut their target price on shares of Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, July 27th. Wall Street Zen upgraded shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Maxim Group increased their price objective on shares of Zevra Therapeutics from $25.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. HC Wainwright restated a “buy” rating and set a $26.00 price objective on shares of Zevra Therapeutics in a research report on Tuesday, June 23rd. Finally, UBS Group reaffirmed a “buy” rating on shares of Zevra Therapeutics in a report on Wednesday, June 24th. Nine analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Zevra Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $27.14.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.